Intranasal Sumatriptan as First-Line Therapy for Pediatric Migraine in the ED

Study Background and Research Question

Migraine is the leading cause of acute headache presentations among children and adolescents in emergency departments (EDs). Traditional outpatient guidelines recommend oral analgesics and triptans at symptom onset, but these recommendations do not always translate to the ED setting, where many patients have already failed initial therapies at home. Up to 71% of pediatric migraine patients arriving at the ED have not responded to oral analgesics, highlighting a critical need for robust, effective abortive strategies for this population (reference study).

Key Innovation from the Reference Study

The referenced work by Hauser Chatterjee et al. represents the largest cohort analysis to date evaluating intranasal (IN) sumatriptan as a first-line abortive treatment for pediatric headache in the ED. Unlike previous protocols that prioritized intravenous (IV) therapies or reserved sumatriptan for second-line use, this study implemented a standardized ED pathway in which IN sumatriptan was positioned as an early intervention. This approach leverages the pharmacological advantages of sumatriptan succinate, a potent 5-HT1 receptor agonist, for rapid symptom relief without the delays and logistic burdens associated with IV access.

Methods and Experimental Design Insights

The authors conducted a retrospective chart review of pediatric patients aged 6–21 years who presented to a single academic ED with migraine or migraine-like headaches between October 2016 and February 2020. Patient demographics, clinical characteristics, pain scores (pre- and post-treatment), treatment patterns, ED length of stay (LOS), charges, and return visits were assessed. Importantly, the analysis compared outcomes for patients receiving IN sumatriptan versus those undergoing IV therapies, providing a direct look at workflow and resource implications in real-world settings.

Protocol Parameters

• IN Sumatriptan Dosage: Administered per institutional protocol, with dosing based on pediatric weight and age, typically aligning with published pharmacokinetic and safety data for intranasal formulations in children.
• Pain Assessment: Numeric pain score (0–10 scale) recorded before and after treatment, median pre-treatment score 7 (IQR 5–8), post-treatment median 2 (IQR 0–4).
• Patient Inclusion: Ages 6–21 years, presenting for acute headache, with a majority having failed pre-hospital oral therapies.
• ED Workflow: IN sumatriptan as first-line abortive therapy, with IV interventions reserved for refractory cases or when IV access was already obtained for other reasons.

Core Findings and Why They Matter

Of 558 eligible patients, 48% received IN sumatriptan in the ED. Among these, 36% were discharged with a prescription for oral sumatriptan. The median pain score reduction was substantial (from 7 to 2), indicating effective acute symptom control. Notably, obtaining IV access was independently associated with a longer ED stay and higher charges, while patients managed primarily with IN sumatriptan experienced more efficient workflows and resource utilization (reference study).

This real-world evidence supports the feasibility and safety of early IN sumatriptan use in pediatric migraine management. The findings are particularly relevant for settings where rapid symptom relief and minimizing invasive procedures are priorities—such as in busy pediatric EDs or where IV access may be challenging.

Comparison with Existing Internal Articles

Recent thought-leadership articles on Sumatriptan Succinate have highlighted its molecular selectivity for 5-HT1B/1D receptors and translational value in migraine and neurovascular research. The present study directly extends these mechanistic insights to clinical workflow, demonstrating that the same serotonergic signaling pathways targeted in preclinical models are relevant for rapid abortive therapy in pediatric patients. Internal resources, such as the translational insights overview, emphasize the compound’s anti-inflammatory and neurovascular actions, which may further support its clinical efficacy and safety profile in acute care settings.

Additionally, protocol guides like this article provide actionable laboratory protocols for sumatriptan’s use in cellular and animal models, supporting mechanistic studies that complement the clinical data presented here. Collectively, these resources create a bridge between laboratory research and emergent clinical application of selective 5-HT1 receptor agonists such as sumatriptan.

Limitations and Transferability

While the study’s retrospective nature and single-center scope limit the generalizability of findings, the large sample size and systematic chart review provide strong real-world signals for the feasibility and efficiency of IN sumatriptan as a first-line agent. The study did not perform a randomized comparison with other standard therapies (such as IV antiemetics or nonsteroidal anti-inflammatory drugs), so direct efficacy comparisons remain to be established. Additionally, the optimal dosing strategies and long-term outcomes for repeated IN sumatriptan use in pediatric populations require further investigation. The results are most transferable to similar tertiary pediatric EDs with access to IN triptan formulations and standardized clinical pathways.

Research Support Resources

For researchers aiming to explore migraine biology, serotonergic signaling, or translational workflows in pediatric migraine models, Sumatriptan (SKU B4981) is available as a validated selective 5-HT1B/1D receptor agonist suitable for both in vitro and in vivo studies. This compound enables detailed interrogation of neurovascular and inflammatory mechanisms, supporting the kinds of translational and mechanistic research highlighted in the reference study. For advanced protocols or workflow troubleshooting, internal articles from APExBIO’s resource network offer additional laboratory guidance and comparative insights.